卡培他滨维持治疗晚期乳腺癌的临床观察

被引：38

作者：

李剑英

季从飞

陈佳

谭清和

机构：

[1] 南通市肿瘤医院肿瘤内科

来源：

中国癌症杂志 | 2014年 / 24卷 / 05期

关键词：

晚期乳腺癌; 卡培他滨; 维持治疗;

D O I：

暂无

中图分类号：

R737.9 [乳腺肿瘤];

学科分类号：

100214 [肿瘤学];

摘要：

背景与目的:卡培他滨是晚期乳腺癌一线治疗方案用药,但在晚期乳腺癌的维持治疗中的研究较少。本文旨在探讨卡培他滨维持治疗晚期乳腺癌的疗效及不良反应。方法:将一线化疗后处于完全缓解(complete response,CR)、部分缓解(partial response,PR)或疾病稳定(stable disease,SD)的62例患者分为2组,卡培他滨治疗组(31例)患者予以单药口服卡培他滨维持治疗,对照组(31例)患者予以定期随访观察。每2个化疗周期后评价疗效。结果:卡培他滨治疗组中位疾病进展时间(time to progression,TTP)为12(2～24)个月,明显高于对照组的7(1～18)个月,且2组差异有统计学意义(P<0.05)。在亚组分析中,未绝经组、激素受体阳性组、HER-2阳性组、有内脏转移组、有肺转移组及既往未接受过卡培他滨化疗组的患者中,卡培他滨治疗组患者的TTP均显著高于对照组患者。卡培他滨治疗组总有效率(CR+PR)为19.4%(6/31),肿瘤控制率(CR+PR+SD)为74.2%(23/31)。主要不良反应为手足综合征及血液学不良反应,其次为胃肠道不良反应,但均可以耐受。卡培他滨治疗组的生活质量评分较对照组明显提高。结论:卡培他滨用于晚期乳腺癌一线治疗后的维持治疗可以延缓疾病进展,提高生活质量。

引用

页码：381 / 386

页数：6

共 6 条

[1]

Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer [J].

Lim, Seungtaek ;

Lee, Soohyeon ;

Han, Jungwoo ;

Park, Byeong-Woo ;

Kim, SeungIl ;

Park, Seho ;

Kim, Joo-Hang ;

Choi, Hye Jin ;

Sohn, Joohyuk .

BREAST, 2013, 22 (06) :1205-1209

[2]

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer [J].

Bisagni, G. ;

Musolino, A. ;

Panebianco, M. ;

De Matteis, A. ;

Nuzzo, F. ;

Ardizzoni, A. ;

Gori, S. ;

Gamucci, T. ;

Passalacqua, R. ;

Gnoni, R. ;

Moretti, G. ;

Boni, C. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) :1051-1057

[3]

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes [J].

Hortobagyi, Gabriel N. ;

Gomez, Henry L. ;

Li, Rubi K. ;

Chung, Hyun-Cheol ;

Fein, Luis E. ;

Chan, Valorie F. ;

Jassem, Jacek ;

Lerzo, Guillermo L. ;

Pivot, Xavier B. ;

Hurtado de Mendoza, Fernando ;

Xu, Binghe ;

Vahdat, Linda T. ;

Peck, Ronald A. ;

Mukhopadhyay, Pralay ;

Roche, Henri H. .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (02) :409-418

[4]

Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study [J].

Alba, Emilio ;

Ruiz-Borrego, Manuel ;

Margeli, Mireia ;

Rodriguez-Lescure, Alvaro ;

Sanchez-Rovira, Pedro ;

Ruiz, Amparo ;

Mel-Lorenzo, Jose Ramon ;

Ramos-Vazquez, Manuel ;

Ribelles, Nuria ;

Calvo, Elisa ;

Casado, Antonio ;

Marquez, Antonia ;

Vicente, David ;

Garcia-Saenz, Jose Angel ;

Martin, Miguel .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (01) :169-176

[5]

Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer [J].

Kusama, Mikihiro ;

Nomizu, Tadashi ;

Aogi, Kenjiro ;

Yoshimoto, Masataka ;

Horikoshi, Noboru ;

Tabei, Toshio ;

Noguchi, Shinzaburo ;

Miura, Shigeto ;

Yoshimura, Norio ;

Kimura, Morihiko ;

Toyama, Kazushige ;

Shin, Eisei .

BREAST CANCER, 2010, 17 (04) :233-240

[6]

Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts [J].

Ishikawa, T ;

Utoh, M ;

Sawada, N ;

Nishida, M ;

Fukase, Y ;

Sekiguchi, F ;

Ishitsuka, H .

BIOCHEMICAL PHARMACOLOGY, 1998, 55 (07) :1091-1097

← 1 →